4/A: Cardio Diagnostics CTO Timur Dogan Amends Form 4 After Stock Purchase
SEC Form 4/A
Cardio Diagnostics' Chief Technology Officer, Timur Dogan, amended a previous Form 4 filing to reflect a stock purchase made on September 6, 2024.
Summary
- Timur Dogan, the Chief Technology Officer of Cardio Diagnostics Holdings, Inc., filed an amended Form 4 on October 9, 2024.
- The amendment relates to a transaction that occurred on September 6, 2024, where Dogan acquired 68,965 shares of common stock at a price of $0.29 per share.
- Following the transaction, Dogan beneficially owns 197,310 shares of common stock.
- The shares are held both individually and jointly with his spouse, who is the issuer's Chief Executive Officer.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing, so the sentiment is neutral.
Industry Context
This filing is a routine disclosure related to insider trading activity, which is common for publicly traded companies. It provides transparency into the transactions of company executives.
Stakeholder Impact
- The transaction may be of interest to shareholders as it reflects the CTO's investment in the company.
Key Dates
| Date | Description |
|---|---|
| 09/06/2024 | Date of stock purchase transaction. |
| 09/23/2024 | Date of original Form 4 filing. |
| 10/09/2024 | Date of amended Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.